Longstanding survival without cancer progression in a patient with endometrial carcinoma treated with leuprolide
Author Information
Author(s): Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A, Dabizzi S, Buccoliero A M, Paglierani M, Taddei G L
Primary Institution: University of Florence
Hypothesis
Can leuprolide treatment lead to long-term survival without cancer progression in patients with endometrial carcinoma?
Conclusion
The patient showed no cancer progression over more than 6 years of leuprolide treatment despite some concerning tumor characteristics.
Supporting Evidence
- The patient was treated with leuprolide for over 6 years.
- No progression of the disease was observed during treatment.
- Histological evaluations showed discrepancies between tumor biology and clinical characteristics.
- Despite concerning tumor features, no local invasion or metastasis was clinically observed.
- The tumor expressed mRNA for LHRH receptors.
Takeaway
One patient with endometrial cancer was treated with a medicine called leuprolide and didn't get worse for over 6 years, even though some tests looked bad.
Methodology
The patient was treated with leuprolide, and various histological and immunohistochemical evaluations were performed on the tumor.
Limitations
The study is based on a single case, which limits the generalizability of the findings.
Participant Demographics
One female patient with endometrial cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website